Related Experiment Videos
[Intravesical therapy of interstitial cystitis]
1Klinik und Poliklinik für Urologie, Westfälische Wilhelms-Universität Münster.
Der Urologe. Ausg. A
|January 4, 2001
Summary
Intravesical therapies like pentosanpolysulfate and heparin can reduce nocturia with minimal side effects. Other agents like DMSO, BCG, and Clorpactin offer varying efficacy and side effect profiles for bladder conditions.
Area of Science:
- Urology
- Pharmacology
Context:
- Intravesical medication instillation offers targeted therapy for bladder conditions.
- This approach achieves high drug concentrations locally with reduced systemic exposure.
Purpose:
- To review the efficacy and side effect profiles of various intravesical medications.
- To compare treatments including pentosanpolysulfate, heparin, DMSO, BCG, and Clorpactin WCS 90.
Summary:
- Pentosanpolysulfate and heparin effectively reduce nocturia with negligible side effects.
- Dimethylsulfoxide (DMSO) provides temporary symptom relief (50-70%) with a distinct odor.
- BCG shows benefit in some patients after several months, while Clorpactin WCS 90 offers moderate-term relief but requires anesthesia due to pain.
Impact:
- Provides a comparative overview of intravesical treatment options for bladder disorders.
- Highlights the trade-offs between efficacy, onset of action, duration, and side effects for different agents.
- Informs clinical decision-making regarding the selection of intravesical therapies based on patient-specific factors and treatment goals.